Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.

ABSTRACT:

Background

Active surveillance (AS) is increasingly accepted for managing low-risk prostate cancer, yet there is no consensus about implementation. This lack of consensus is due in part to uncertainty about risks for disease progression, which have not been systematically compared or integrated across AS studies with variable surveillance protocols and dropout to active treatment.

Objective

To compare risks for upgrading from a Gleason score (GS) of 6 or less to 7 or more across AS studies after accounting for differences in surveillance intervals and competing treatments and to evaluate tradeoffs of more versus less frequent biopsies.

Design

Joint statistical model of longitudinal prostate-specific antigen (PSA) levels and risks for biopsy upgrading.

Setting

J

SUBMITTER: Inoue LYT 

PROVIDER: S-EPMC5752581 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature